Readers of this blog will know that I've commented several times on the trials and tribulations of various treatments for non-small cell lung cancer therapies - mostly that they've failed to meet their endpoints in pivotal phase 3 clinical trials.
Yesterday, ArQule announced a more successful result for its ARQ 197 plus erlotinib in a phase 2 trial. Sally Church does a great job discussing the mechanism of this particular treatment and its merits (or lack thereof). As Derek Lowe, in his blog In the Pipeline, frequently reminds us, there is a big difference between a phase 2 and phase 3 trial. We'll see how this pans out further down the pipeline.
In the meantime, follow the link below to Sally's site for a more thorough discussion of the ARQ 197 molecule.